OT-82, a preclinical stage drug candidate developed at Roswell Park Comprehensive Cancer Center (RPCCC) Buffalo, shows promise as a treatment to fight high-risk leukemia. Licensed for R&D and commercialization to OncoTartis, a biotech venture organized by RPCCC’s professor Andrei Gudkov, they announced positive preclinical research evidence generated by a collaboration with Australia’s Children’s Cancer Institute with the announcement of published results in journal Leukemia. OT-82 is now in a Phase I clinical trial. The IP has the attention of a Russian Billionaire and the largest Russian pharmaceutical company—both representing the first major venture investment in the sponsor.
A Potentially Powerful New Weapon Against Blood Cancers?
A significant proportion of blood cancers in both adults and children remain resistant to current treatments and are often deadly. Someone dies from some form of blood cancer in the United States every 9 minutes according to the Leukemia & Lymphoma Society.
The Investigational Drug: OT-82
OT-82, a NAMPT (NicotinAMide Phosphoribosyl Transferase) inhibitor, was originally developed at Buffalo, New York’s Roswell Park Comprehensive ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).